Table 2.
Main characteristics and genotype of studies included on myopathy due to statin treatment in the meta-analysis
| Case | Control | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First author | Year | Country | Gende (male %) | Age | follow-up period | Treatment protocal | The definition of the case | CC | CT | TT | CC | CT | TT | HWE |
| Fiegenbaum [10] | 2005 | Brazil | 25.3 | 59.2 ± 10.7 | 6 months | simvastatin 20 mg/d | Myalgia | 5 | 10 | 0 | 21 | 46 | 32 | 0.557 |
| Hoenig [15] | 2011 | Australia | 79 | 67.6 ± 10 | 6 weeks | atorvastatin 80 mg/d | Myalgia | 1 | 2 | 7 | 18 | 46 | 43 | 0.349 |
| Ferrari [16] | 2014 | NA | 39.4 | NA | more than 5 months | atorvastatin, rosuvastatin or simvastatin | statin-induced elevations in serum CK of >3 × UNL | 4 | 17 | 12 | 11 | 17 | 5 | 0.707 |
NA Not applicable